ATAI launches IntroSpect Digital Therapeutics, appoints veteran software engineer David Keene as CEO

November 8, 2020 Articles 7:21 pm

Today, ATAI Life Sciences (“ATAI” or the “Company”), a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of its digital therapeutic platform IntroSpect Digital Therapeutics, Inc. (“IntroSpect”)David Keene, who brings almost two decades of experience in tech- and healthcare-related fields, will serve as CEO and will be leading ATAI’s efforts to bring digital therapeutics (DTx) and precision psychiatry to bear on the mental health epidemic.

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit